Guaifenesin

Sneezing, Tracheitis, Emphysema + 43 more

Treatment

5 FDA approvals

20 Active Studies for Guaifenesin

Treatment for

Sneezing

What is Guaifenesin

Guaifenesin

The Generic name of this drug

Treatment Summary

Guaifenesin is a medication approved by the FDA in 1952 and is used to help clear chest congestion. It is available both over-the-counter and as a generic drug. Although its exact mechanism is unknown, it is believed to make coughing more productive. In 2007, the FDA received a petition asking them to notify the public about not using guaifenesin for children under 6 years of age. After negotiation with major manufacturers, labels were changed to not use the drug in children under 4 years of age. Recent research has also suggested that guaifenesin may possess anticonvulsant and muscle relaxant

Goyescas 7 Syrups Original Cough and Cold

is the brand name

image of different drug pills on a surface

Guaifenesin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Goyescas 7 Syrups Original Cough and Cold

Guaifenesin

1958

497

Approved as Treatment by the FDA

Guaifenesin, also called Goyescas 7 Syrups Original Cough and Cold, is approved by the FDA for 5 uses which include Productive cough and induction of Productive cough .

Productive cough

induction of Productive cough

chest congestion

Phlegm

Coughing

Effectiveness

How Guaifenesin Affects Patients

Guaifenesin is a type of medication that helps to make coughing more productive. It works by decreasing the stickiness and tension of the mucus in your airways, making it easier for the body to move it out. This helps to clear the airways of secretions like phlegm, making coughing more effective.

How Guaifenesin works in the body

Guaifenesin is believed to work by increasing mucus secretions and irritating the stomach, triggering a reflex that causes the glands to produce a less viscous mucus mixture. This mixture can help flush out difficult-to-access congealed mucus from the airways. It is thought that guaifenesin may also act as an anticonvulsant and muscle relaxant, possibly by blocking NMDA receptors.

When to interrupt dosage

The prescribed amount of Guaifenesin is subject to the established affliction, such as Pollen Allergy, Drug Allergy and Allergic Reaction. The measure of dosage fluctuates depending on the mode of administration outlined in the table beneath.

Condition

Dosage

Administration

Phlegm

20.0 mg/mL, , 100.0 mg/mL, 40.0 mg/mL, 200.0 mg/mL, 400.0 mg, 50.0 mg/mL, 200.0 mg, 600.0 mg, 225.0 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 350.0 mg/mL, 100.0 mg, 10.0 mg/mL, 150.0 mg, 120.0 mg/mL, 395.0 mg, 388.0 mg/mL, 187.0 mg/mL, 388.0 mg, 25.0 mg/mL, 175.0 mg/mL, 60.0 mg/mL, 70.0 mg/mL, 90.0 mg/mL, 150.0 mg/mL, 75.0 mg/mL, 8.33 mg/mL, 380.0 mg, 390.0 mg, 125.0 mg/mL, 88.0 mg/mL, 1200.0 mg, 30.0 mg/mL, 375.0 mg, 35.0 mg, 2.0 mg/mL, 240.0 mg, 120.0 mg, 50.0 mg, 24.99 mg, 385.0 mg, 198.0 mg, 190.0 mg, 835.0 mg, 800.0 mg, 350.0 mg, 550.0 mg, 288.0 mg, 775.0 mg, 580.0 mg, 180.0 mg, 78.0 mg/mL, 780.0 mg, 1000.0 mg, 575.0 mg, 315.0 mg, 1100.0 mg, 650.0 mg, 15.0 mg/mL, 275.0 mg, 300.0 mg, 360.0 mg, 211.0 mg/mL, 35.0 mg/mL, 80.0 mg/mL, 4.2 mg/mL, 0.2 mg, 41.6 mg, 0.007 mg/mg, 0.21 mg/mg, 20.84 mg, 39.6 mg/mL, 0.4 mg/mg, 25.0 mg, 4.0 mg/mL, 37.5 mg/mL, 5.0 mg/mL, 22.1 mg/mL, 10000.0 mg/mL

, Liquid, Liquid - Oral, Solution, Oral, Solution - Oral, Powder, for solution, Powder, for solution - Oral, Syrup, Syrup - Oral, Tablet, coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Tablet, extended release, Tablet, film coated, Tablet, extended release - Oral, Tablet, coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Kit, Tablet, Tablet - Oral, Solution / drops, Capsule, coated - Oral, Capsule, coated, Capsule, Capsule - Oral, Suspension / drops, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Solution / drops - Oral, Suspension / drops - Oral, Solution / drops - Nasal, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Granule - Oral, Granule, Elixir - Oral, Nasal, Elixir, Suppository - Rectal, Suppository, Kit; Tablet, Kit; Tablet - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Rectal, Capsule; Kit - Oral, Capsule; Kit, Kit - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Gel - Oral, Gel, Nasal; Oral, Powder, Powder - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Common Cold

Whooping Cough

House dust allergy

Hives

Acute Bronchitis

Exanthema

Bronchial Spasm

Rhinitis, Allergic

Productive cough

Coughing

Rhinorrhea

Fever

Influenza

Chronic Obstructive Pulmonary Disease

Tobacco Use

Pharyngitis

Bronchitis, Chronic

Food Hypersensitivity

Asthma

Warnings

Guaifenesin Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Guaifenesin may interact with Pulse Frequency

Common Guaifenesin Drug Interactions

Drug Name

Risk Level

Description

Guaifenesin Toxicity & Overdose Risk

Overdosing on guaifenesin can cause nausea and vomiting. Though no studies have been done on pregnant women, one study found that babies of mothers who took guaifenesin had increased instances of inguinal hernias. Guaifenesin can be found in small amounts in breast milk, so care should be taken when considering taking the drug. The toxic dose of guaifenesin for rats is 1510mg/kg.

image of a doctor in a lab doing drug, clinical research

Guaifenesin Novel Uses: Which Conditions Have a Clinical Trial Featuring Guaifenesin?

At present, 309 clinical trials are being conducted to determine the potential of Guaifenesin to relieve symptoms of Rash, Sore Throat and Cough.

Condition

Clinical Trials

Trial Phases

Tracheitis

0 Actively Recruiting

Fever

2 Actively Recruiting

Not Applicable, Phase 4

Asthma

92 Actively Recruiting

Phase 1, Phase 4, Early Phase 1, Phase 2, Not Applicable, Phase 3

Chronic Obstructive Pulmonary Disease

76 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Coughing

0 Actively Recruiting

chills occurring with fever

0 Actively Recruiting

Influenza

29 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 1, Phase 3

Tobacco Use

0 Actively Recruiting

Nasal Congestion

0 Actively Recruiting

Rhinitis, Allergic

0 Actively Recruiting

Pain

0 Actively Recruiting

Coughing

0 Actively Recruiting

excess mucus or phlegm

0 Actively Recruiting

Coughing

0 Actively Recruiting

Laryngitis

0 Actively Recruiting

Whooping Cough

0 Actively Recruiting

Exanthema

0 Actively Recruiting

Coughing

0 Actively Recruiting

Emphysema

4 Actively Recruiting

Phase 2, Not Applicable

Acute Bronchitis

1 Actively Recruiting

Not Applicable

Guaifenesin Reviews: What are patients saying about Guaifenesin?

Patient Review

3/28/2018

Guaifenesin for Cough

I have thyroid disease and can't take most medications, but this product really helped me. It's not a miracle cure, but it definitely loosens up the mucus in your body. I've only been taking it for 24 hours, but my cough has dramatically lessened. When I cough now, there is actually mucus instead of just dry hack. So glad to finally have found something that works for me!

Patient Review

3/9/2012

Guaifenesin for Cold Symptoms

I Began taking this medication when I had a cold, and after two days I noticed that my fibromyalgia pain had disappeared. I now take it regularly to manage my muscle pain--I really couldn't do without it!

Patient Review

9/13/2013

Guaifenesin for Cough

This is the only treatment that has helped my reflux-induced coughing and gagging. It's really effective!

3.7

Patient Review

11/30/2011

Guaifenesin for Cold Symptoms

I use this medication to help relieve pressure and pain in my ears that is caused by mucus buildup.

1.7

Patient Review

2/4/2013

Guaifenesin for Cold Symptoms

I found that this really didn't help with my thinning mucus, unfortunately. It did help a bit with my cough, though.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about guaifenesin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does guaifenesin keep you awake?

"No, Guaifenesin typically does not make it difficult to sleep. However, some people have reported that they have experienced this side effect. If you experience this, you are advised to take the recommended dose in the morning and early afternoon."

Answered by AI

When should you not take guaifenesin?

"If you have a cough with mucus, guaifenesin (Mucinex) may help. Do not use for more than 7 days unless directed by a provider. If your cough does not improve or you develop other symptoms, such as a fever or headache, stop taking this medication and talk to your provider."

Answered by AI

What is the difference between Mucinex and guaifenesin?

"The active ingredient in Mucinex is guaifenesin, a drug that belongs to a class of drugs known as expectorants. Guaifenesin is a drug that can be bought over the counter or with a prescription. It's also one of the common ingredients in combination cold and flu medications like Robitussin DM."

Answered by AI

Will guaifenesin make you sleepy?

"Headache. Nausea. Vomiting

The most common side effects of guaifenesin are dizziness, drowsiness, headache, nausea, and vomiting."

Answered by AI

Clinical Trials for Guaifenesin

Have you considered Guaifenesin clinical trials?

We made a collection of clinical trials featuring Guaifenesin, we think they might fit your search criteria.

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+

All Sexes

Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available

Has No Placebo

Stanford University

Jeff Swigris, DO, MS

Minnesota Health Solutions

Have you considered Guaifenesin clinical trials?

We made a collection of clinical trials featuring Guaifenesin, we think they might fit your search criteria.

Image of Vanderbilt University Medical Center in Nashville, United States.

High vs. Standard Dose Influenza Vaccines for Flu

18+

All Sexes

Nashville, TN

This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center. Lung transplantation is a life-saving therapy for patients with advanced lung disease, and is also associated with an improvement in quality of life. However, due to the need for life-long immunosuppression to prevent acute cellular rejection and chronic lung allograft dysfunction ("chronic rejection"), lung transplant recipients are at risk for developing major infections. In fact, one-year survival is 85%, with infection being the leading cause of death within the first year post-transplant. We will conduct a follow-up phase II, randomized, double-blind trial to assess the impact of subsequent administration of two doses of HD-IIV compared to two doses of SD-IIV among lung recipients during the early post-transplant period. Demonstration of improved immunogenicity from two doses of HD-IIV over consecutive influenza seasons would provide potential broad benefit in reducing influenza disease and its associated complications in lung transplant recipients. Moreover, studying vaccine immunogenicity and safety in the same participants over consecutive years can provide insight into the influence of immunosuppression levels and allograft aging on vaccine-mediated immune modulation. This proposed study design will contribute significantly to influenza vaccination guidance and policy for the highly vulnerable lung transplant population. This proposed study is designed to address several key knowledge gaps in vaccine-mediated protection of lung transplant recipients against influenza: * Is there increased immunogenicity with administration of one or two doses of HD-IIV or SD-IIV in the subsequent season compared to two doses of HD-IIV or SD-IIV in the first season? * What is the durability of the humoral and cellular immune response between influenza seasons and does two doses of HD-IIV or SD-IIV sustain higher HAI titers compared to two doses of HD-IIV or SD-IIV in the first season? * What is the impact of maintenance immunosuppression levels on influenza vaccine immunogenicity within the same participant? * Will the optimal immunogenic vaccination strategy be associated with an acceptable long-term safety profile over successive influenza seasons, including injection-site and systemic reactions, allosensitization, and organ rejection?

Phase 2

Recruiting

Has No Placebo

Vanderbilt University Medical Center

Natahsa Halasa, MD, MPH